Reevaluating erythropoiesis-stimulating agents

New England Journal of Medicine

Volumn 362, Issue 18, 2010, Pages 1743-

  Cotter, Dennis J ^a  

^a Medical Technology and Practice Patterns Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; FOOD AND DRUG ADMINISTRATION; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBIN DETERMINATION; LETTER; MEDICARE; PRIORITY JOURNAL; RISK;

ANEMIA; DRUG AND NARCOTIC CONTROL; ERYTHROPOIETIN; HEMATINICS; HEMOGLOBINS; HUMANS; REFERENCE VALUES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 77951868347     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. Singh AK. Does TREAT give the boot to ESAs in the treatment of CKD anemia? J Am Soc Nephrol 2010;21:2-6.
2. Pfeffer MA, Burdmann EA, Chen C-Y, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361:2019-2032
3. Cotter D, Thamer M, Narasimhan K, Zhang Y, Bullock K. Translating epoetin research into practice: the role of government and the use of scientific evidence. Health Aff (Millwood) 2006;25:1249-1259 (Pubitemid 44497623)
4. Szczech LA, Barnhart HX, Inrig JK, et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 2008;74:791-798
5. Pollack A. F.D.A. plans safety check of 3 drugs for anemia. New York Times. January 6, 2010. (Accessed March 31, 2010, at http://www.nytimes.com/ 2010/01/07/business/07fda.html.)